# Why the Same THC Dose Behaves Differently at 30 and at 70 > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-pharmacokinetics-in-older-adults/ > **Published:** 2026-09-04T22:55:52-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:39:26-04:00 > **Clinical Summary:** Cannabis pharmacokinetics in older adults: what plasma THC, 11-OH-THC, and 11-COOH-THC levels show, what age changes, and what the evidence does not settle. --- CED Clinical Relevance #46Strong Clinical RelevanceOlder patients are the fastest-growing group asking about [medical cannabis](https://cedclinic.com/cbd-gummies-for-sexual-enhancement-evidence/), and they are the group most likely to be harmed by a dose chosen from a younger person’s playbook. The pharmacokinetic literature is thin here, and knowing exactly how thin is part of practicing responsibly. Two people can take an identical milligram dose of THC and end up with different blood levels and very different experiences. Age contributes to that difference, though not in the direction most people assume. Here is what the controlled pharmacokinetic literature establishes, and where it stops. Clinical Insight | CED Clinic Plasma cannabinoid measurement answers a narrower question than most people expect. It tells you how much of a compound reached the bloodstream and how fast it was cleared. It does not tell you how a patient feels, and the correlation between the two is weak even in carefully controlled laboratory conditions. In older adults, the practical concern is rarely that blood levels run wildly high. It is that the same blood level lands in a body with less physiologic reserve, more competing medications, and a lower tolerance for an afternoon of sedation. [Cannabis Pharmacokinetics](https://cedclinic.com/cbd-gummies-pharmacokinetics-effects-evidence-use/)Older AdultsTHC MetabolismDosing and SafetyClinical Reference AudiencePatients, caregivers, and cliniciansPrimary TopicPlasma cannabinoid concentrations and age-related pharmacokineticsSource[Read the full source](https://doi.org/10.1016/j.drugalcdep.2026.113160) Why This Matters Most published cannabinoid pharmacokinetic work was done in young, healthy, often cannabis-experienced volunteers. Applying those curves to a 74-year-old on four other medications is an extrapolation, not a measurement, and it is worth being honest about that when a patient asks what dose is right. The single controlled pharmacokinetic study of oral THC conducted specifically in healthy adults over 65 enrolled twelve people. That is the evidence base. Everything beyond it is inference from general geriatric pharmacology, which is reasonable to use but should not be presented as established cannabinoid science. What a Plasma Cannabinoid Panel Is Actually Measuring Four compounds account for most of what shows up when plasma is analyzed after cannabis use. Delta-9-tetrahydrocannabinol is the parent psychoactive molecule. 11-hydroxy-THC is an active hepatic metabolite. 11-nor-9-carboxy-THC is the inactive terminal metabolite that persists longest. THCA, the acid form present in unheated plant material, generally reaches plasma in meaningful amounts only when raw or under-decarboxylated preparations are used. The ratio between these compounds is route-dependent in a way that matters clinically. In a controlled comparison published in *Clinical Pharmacology and Therapeutics*, the plasma ratio of 11-hydroxy-THC to THC was roughly 1 to 10 or 1 to 20 after intravenous dosing, but approximately 0.5 to 1 up to 1 to 1 after oral dosing. Swallowed cannabis passes through the liver before reaching the circulation, generating proportionally far more of the active metabolite. That is the pharmacologic reason an edible can feel qualitatively different from an inhaled dose of nominally equal size. The patient is not imagining it, and the difference is not a matter of potency alone. What Controlled Work in Adults Over 65 Actually Found The most directly relevant trial is a phase 1, randomized, double-blind, double-dummy, placebo-controlled crossover study published in *European Neuropsychopharmacology* in 2014 by Ahmed and colleagues at Radboud University Medical Center. Twelve healthy older adults, six of them men, with a mean age of 72 plus or minus 5 years, received single oral doses of 3 mg, 5 mg, or 6.5 mg of a tablet formulation of THC, or matching placebo. Data from eleven participants were analyzed. THC was safe and well tolerated in this group. The most common adverse events were drowsiness, reported in 27 percent of cases, and dry mouth, in 11 percent. Participants reported more adverse events at 6.5 mg than at 3 mg, at 5 mg, or on placebo. Among those whose peak concentration fell inside the two-hour sampling window, maximum plasma THC ranged from 1.42 to 4.57 ng/mL and time to peak ranged from 67 to 92 minutes. Two findings deserve emphasis. Inter-individual variability in plasma concentration was wide, meaning the same milligram dose produced substantially different exposures across a group of healthy people chosen for their similarity. And the pharmacodynamic effects observed were smaller than effects previously reported in young adults given comparable doses. The Physiology Behind Age-Related Differences Cannabinoids are highly lipophilic. After intravenous THC, the apparent volume of distribution is on the order of 10 L/kg, which reflects extensive movement out of plasma and into lipid-rich tissue. Terminal half-life for THC in that same study ranged from 25 to 36 hours regardless of route or sex. Body composition therefore has a direct bearing on how a dose distributes, and body composition shifts with age. The persistence of stored cannabinoid is measurable. In 28 chronic frequent cannabis smokers studied under monitored abstinence for up to 33 days, plasma THC remained at or above 2 micrograms per liter in 16 of 28 participants at 48 hours, and THC was still detectable in some participants after 30 days. That is a study of frequent users, not of older adults, but it demonstrates that the lipid compartment releases cannabinoid back into circulation over a long tail. Genetics contribute at least as much as age to inter-individual spread. In 43 healthy volunteers given oral THC, carriers of two copies of the CYP2C9*3 variant showed median THC exposure roughly threefold higher than people with two copies of the common allele, alongside 70 percent lower concentrations of the carboxy metabolite and a trend toward more sedation. Clinicians are not genotyping cannabis patients, and this is a reminder that the variability seen in the clinic has real pharmacologic origins. Does Adding CBD Raise THC Blood Levels? The Evidence Splits This question comes up constantly, and the honest answer is that controlled studies disagree. A randomized, double-blind, placebo-controlled crossover trial published in *Drug and Alcohol Dependence* in 2026 by Hall and colleagues compared vaporized weight-adjusted preparations: THC alone at 8 mg per 75 kg, THC plus CBD at 8 mg THC and 24 mg CBD per 75 kg, and placebo. Forty-eight participants were enrolled and 35 had complete pharmacokinetic datasets. The THC plus CBD condition produced significantly higher plasma THC, 11-hydroxy-THC, and carboxy-THC by log-transformed area under the curve and peak concentration. An earlier randomized double-blind study published in *Clinical Chemistry* reached the opposite conclusion. Nine cannabis smokers received 5 and 15 mg oral THC, low-dose and high-dose oromucosal THC and CBD spray, and placebo. There were no statistically significant differences in peak concentration, time to peak, or area under the curve between matched oral THC and spray doses, which the authors read as evidence that CBD modulation of THC effects is not a pharmacokinetic phenomenon at those doses. Different routes, different doses, different populations, opposite conclusions. A patient who reports that a high-CBD product feels stronger or weaker than expected is describing something the literature has not resolved, and telling them otherwise would be overreach. Where the Age Question Remains Genuinely Open The 2026 vaporized cannabis trial set out explicitly to test whether cannabinoid pharmacokinetics are moderated by age, and found no strong evidence of age-related differences. That sounds like an answer until the age groups are examined: the comparison was between participants aged 16 to 17 and participants aged 26 to 29. It is a valuable adolescent versus young adult comparison. It says nothing about a 70-year-old. No published controlled trial has directly compared plasma cannabinoid pharmacokinetics between young adults and adults over 65 under matched dosing conditions. The older-adult data and the young-adult data come from separate studies using different formulations, routes, sampling schedules, and analytical methods. Cross-study comparison of that kind can generate hypotheses. It cannot settle them. Anyone who tells you confidently that older adults clear THC more slowly, or more quickly, is going beyond the published record. The physiologic rationale for expecting differences is sound. The measurement has not been done. What This Means for Dosing Decisions The practical implications do not depend on resolving the pharmacokinetic question. Start lower than feels necessary. Increase slowly, over days rather than within a session. Hold the route constant while titrating, because switching between inhaled and oral changes the metabolite profile and not merely the dose. For an older patient specifically, the relevant risks are sedation, orthostatic symptoms, and additive effects with other central nervous system agents. Fall risk, not blood level, is the outcome worth protecting. A dose that produces a modest plasma concentration but a two-hour period of unsteadiness is the wrong dose regardless of what the pharmacokinetics look like. Medication review comes before dose selection. Cannabinoids are metabolized by cytochrome P450 enzymes that handle a large share of commonly prescribed drugs, and older patients carry more of those prescriptions. That conversation belongs with a clinician who has the full medication list in front of them. Pharmacokinetic Reference: Cannabinoid Analytes and AgeDelta-9-THCParent psychoactive compound. Plasma peaks within minutes of inhalation; low and erratic after oral dosing (Ohlsson 1980, *Clin Pharmacol Ther* 28:409, PMID 6250760).11-Hydroxy-THCActive hepatic metabolite. Ratio to THC is roughly 0.5:1 to 1:1 after oral dosing versus about 1:10 to 1:20 after intravenous (Wall 1983, *Clin Pharmacol Ther* 34:352, PMID 6309462).11-Nor-9-carboxy-THCInactive terminal metabolite. Persists longest; still detectable in some frequent users after 30 days of monitored abstinence (Karschner 2016, *Drug Test Anal* 8:682, PMID 26097154).THCAAcid form present in unheated plant material. Reaches plasma in meaningful amounts mainly when raw or under-decarboxylated preparations are used.Systemic availability by routeSmoked THC averaged 18 plus or minus 6 percent; oral THC 6 plus or minus 3 percent, in 11 healthy adults (Ohlsson 1980).Terminal half-life25 to 36 hours for THC in both men and women, irrespective of route (Wall 1983).Volume of distributionAbout 10 L/kg after intravenous THC, reflecting extensive distribution into lipid-rich tissue (Wall 1983).CYP2C9 genotype effectCYP2C9*3 homozygotes showed roughly threefold higher oral THC exposure and 70 percent lower carboxy-THC than common-allele homozygotes, in 43 volunteers (Sachse-Seeboth 2009, *Clin Pharmacol Ther* 85:273, PMID 19005461).Measured in adults over 65Oral THC 3 to 6.5 mg in 11 healthy adults, mean age 72: peak plasma 1.42 to 4.57 ng/mL, time to peak 67 to 92 minutes, wide inter-individual variability (Ahmed 2014, *Eur Neuropsychopharmacol* 24:1475, PMID 25035121).CBD co-administrationVaporized THC plus CBD raised THC and metabolite exposure versus THC alone in 35 analyzed participants (Hall 2026, PMID 42033891); matched oromucosal versus oral dosing showed no pharmacokinetic difference in 9 participants (Karschner 2011, PMID 21078841).What plasma level does not tell youSubjective effect lags peak plasma concentration and correlates with it only weakly, which is why blood level is a poor proxy for how someone feels (Ohlsson 1980; Hollister 1981, PMID 6271822). How Strong Is This Evidence? The individual pharmacokinetic studies cited here are methodologically sound: randomized, controlled, blinded where feasible, with validated mass spectrometry assays. Their limitation is not quality but scope. Sample sizes run from 9 to 48 participants, which is typical and appropriate for intensive pharmacokinetic sampling but leaves little room for subgroup analysis. For the specific question of how age changes plasma cannabinoid handling, the evidence is weak by design rather than by execution. The older-adult data come from one 12-person trial. No study has enrolled young and older adults into the same protocol and compared them directly. That is a gap in the literature, not a controversy within it. Where This Paper Deserves Skepticism Cross-study comparison is doing more work here than it should. The oral THC data in older adults used a specific tablet formulation with a two-hour sampling window, which was too short to capture peak concentration in some participants. Comparing those numbers to inhaled data from a different laboratory using different analytics is suggestive at best. The frequently repeated claim that older adults metabolize THC more slowly because of reduced hepatic enzyme activity is a plausible extrapolation from general geriatric pharmacology, not a finding from cannabinoid research. The most direct measurement available found smaller pharmacodynamic effects in older adults than had been reported in younger people, which is not what a simple slower-clearance model would predict. What This Paper Does Not Show None of this work shows that a particular dose is safe or effective for an older patient with a particular condition. Pharmacokinetic studies in healthy volunteers measure exposure, not therapeutic benefit, and healthy volunteers over 65 are not the same population as frail patients over 80. The literature also does not establish a plasma concentration that corresponds to impairment, therapeutic effect, or safety to drive. The correlation between plasma THC and subjective or psychomotor effect is weak enough that attempts to define such a threshold have repeatedly failed. How This Fits With the Broader Clinical Conversation [Cannabis medicine](https://cedclinic.com/cbd-gummies-fatty-liver-evidence-practical-considerations/) has an evidence distribution problem. The population using medical cannabis skews older every year, while the population studied in controlled pharmacology skews young. That mismatch is not unique to cannabis, but it is unusually wide here because the research was historically designed around abuse liability rather than therapeutic use. The CYP2C9 finding points toward where this field should go next. A threefold difference in exposure attributable to a single common genetic variant is larger than most of the age effects being speculated about, and it is measurable today. Pharmacogenomic stratification would likely explain more clinical variability than chronological age does. Dr. Caplan’s Take In clinic, the age conversation almost never turns on metabolism. It turns on what a patient can afford to lose. A 28-year-old who feels foggy for an hour has an inconvenience. An 82-year-old who feels foggy for an hour has a fall risk, and a fall changes the rest of their life. That is why I start older patients at doses that sound almost pointlessly small to people who have used cannabis recreationally. The goal is to find the bottom of the effective range and stop there, not to find the top of the tolerable range and back off. Those two approaches produce very different outcomes in the same patient. I also tell older patients plainly that the research on their age group is thin. They tend to appreciate hearing it. It is a more useful basis for shared decision-making than false precision about blood levels. Clinical Bottom Line Plasma cannabinoid levels vary widely between people at the same dose, and route of administration changes the metabolite profile more than the dose does. Direct comparisons between young and older adults have not been performed. For older patients, choose the starting dose based on fall risk and medication interactions rather than on pharmacokinetic reasoning the literature cannot yet support. What a Careful Reader Should Take Away Carry forward three things: the metabolite ratio shifts substantially with route, inter-individual variability is large and partly genetic, and the direct age comparison has not been done. Leave behind any confident statement about how quickly older adults clear THC relative to younger ones. That claim circulates widely and does not have a controlled trial behind it. Evidence Interpretation Guide Table of Contents - [How to read pharmacokinetic data without over-reading it](#How_to_read_pharmacokinetic_data_without_over-reading_it) - [Plasma Cannabinoids and Age, Seen From Eight Angles](#Plasma_Cannabinoids_and_Age_Seen_From_Eight_Angles)[What this means if you are over 65](#What_this_means_if_you_are_over_65) - [What to document and what to ask](#What_to_document_and_what_to_ask) - [The age claim outruns the evidence](#The_age_claim_outruns_the_evidence) - [Design limits worth naming](#Design_limits_worth_naming) - [How the picture has changed since 1980](#How_the_picture_has_changed_since_1980) - [Applying this at the level of a single dose](#Applying_this_at_the_level_of_a_single_dose) - [The study that should be run](#The_study_that_should_be_run) - [Why per se blood limits are hard to justify](#Why_per_se_blood_limits_are_hard_to_justify) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## How to read pharmacokinetic data without over-reading it The Research QuestionHow do plasma concentrations of THC and its metabolites vary by route, by co-administered CBD, and by participant age?The Patient QuestionIf I am older, should I expect cannabis to hit me harder or last longer than it would have at 30?The Bottom LineRoute and individual genetics move plasma cannabinoid levels substantially. Age plausibly does too, but no controlled study has measured young against older adults under matched conditions. CED Perspective Lens ## Plasma Cannabinoids and Age, Seen From Eight Angles A pharmacokinetic reference read through the lenses that matter in clinical practice. Lens OverviewControlled studies establish how route and genotype shape plasma cannabinoid levels. The direct young versus older adult comparison remains unmeasured. #### What this means if you are over 65 The clearest finding from the one controlled study in healthy adults over 65 is that people given identical oral doses ended up with quite different blood levels. That variability is not a sign of anything being wrong. It is the normal state of affairs with a lipophilic compound. The practical consequence is that someone else’s dose is not information about your dose. Starting low and moving slowly is not excessive caution in this context; it is the only way to find your own number. Lens takeawayIdentical doses produce different blood levels in different people. Find yours rather than borrowing someone else’s. #### What to document and what to ask Record route, product cannabinoid content, timing relative to other medications, and the specific functional outcome being tracked. Plasma levels are not clinically actionable and are not worth ordering outside a research or forensic context. The interaction review matters more than the dose calculation. Cannabinoids are handled by cytochrome P450 enzymes shared with anticoagulants, antiepileptics, and several psychiatric medications, and older patients are the group most likely to be taking them. Lens takeawayRoute, product content, and the full medication list are the actionable data. Plasma level is not. #### The age claim outruns the evidence A great deal of published commentary asserts that older adults metabolize cannabinoids more slowly, citing general principles of geriatric pharmacology rather than cannabinoid measurements. The reasoning is respectable. The citation trail does not lead to data. The one trial that explicitly examined age moderation compared adolescents with people in their late twenties and found no strong age effect. That result is often quoted without the age ranges attached, which makes it sound like it addressed older adults. It did not. Lens takeawayCheck the age ranges before accepting any claim about cannabis and aging. #### Design limits worth naming The older-adult trial sampled plasma for only two hours, and peak concentration fell outside that window for some participants. Reported peak values therefore describe a subset, not the whole sample, and the study says so. Sample sizes across this literature run from 9 to 48. Those are appropriate numbers for intensive serial sampling and inappropriate numbers for detecting modest between-group differences. Lens takeawayThese are small, well-run studies. Treat them as descriptive, not definitive. #### How the picture has changed since 1980 The foundational route comparisons date to 1980 and 1983 and have held up remarkably well. Smoked systemic availability near 18 percent, oral near 6 percent, and a metabolite ratio that flips with route are still the reference numbers. What has changed is analytical sensitivity. Modern assays detect cannabinoid in plasma weeks after last use, which reframed the old assumption that THC clears within days. Lens takeawayThe route pharmacology is old and durable. The clearance picture is newer and longer than once believed. #### Applying this at the level of a single dose Hold one variable constant at a time. If the route changes, the metabolite profile changes, and any conclusion drawn about the dose is confounded. If the product changes, the actual delivered cannabinoid changes even when the label number is the same. Give an oral dose a full evening before judging it. Time to peak in the older-adult study ranged past 90 minutes, and that was with a standardized tablet on a controlled schedule. Lens takeawayOne variable at a time, and enough patience to let an oral dose finish arriving. #### The study that should be run A single protocol enrolling matched young and older adults, randomized to identical oral and inhaled doses, with sampling long enough to capture peak and decline in every participant, would settle the central question in this article. Adding CYP2C9 genotyping to that protocol would cost little and would clarify how much of the variability currently attributed to age belongs to genetics instead. Lens takeawayOne matched-cohort crossover study with genotyping would answer most of what remains open. #### Why per se blood limits are hard to justify Several jurisdictions define impairment by a plasma or whole blood THC threshold. The pharmacokinetic record does not support that approach: subjective and psychomotor effects lag peak concentration and correlate with it weakly. Detectability after weeks of abstinence in frequent users compounds the problem, because a measurable level can reflect stored cannabinoid rather than recent use. Lens takeawayBlood concentration is a poor measure of impairment, and the pharmacology has said so since 1980. Related Reading at CED ClinicContinue exploring the evidence[Cannabis and Older Adults: Benefits, Risks, and Clinical Guidance](https://cedclinic.com/cannabis-and-older-adults-what-the-research-shows-about-benefits-risks-and-clinical-guidance/) The broader clinical picture for patients over 65, beyond pharmacokinetics. [Read the guidance](https://cedclinic.com/cannabis-and-older-adults-what-the-research-shows-about-benefits-risks-and-clinical-guidance/)[Does CBD Change How Your Body Handles THC?](https://cedclinic.com/cbd-thc-pharmacokinetic-interaction-meta-analysis/) A closer look at the CBD and THC interaction question that controlled studies have not resolved. [See the meta-analysis](https://cedclinic.com/cbd-thc-pharmacokinetic-interaction-meta-analysis/)[Edibles vs Smoking: Which Cannabis Method Is Right for You?](https://cedclinic.com/edibles-vs-smoking-best-way-to-use-cannabis/) Why the route changes the metabolite profile, not just the timing. [Compare the routes](https://cedclinic.com/edibles-vs-smoking-best-way-to-use-cannabis/) Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) ## Frequently Asked Questions Do older adults metabolize THC more slowly than younger adults? No controlled study has measured this directly. The claim is an extrapolation from general geriatric pharmacology rather than a finding from cannabinoid research. The one trial that tested age moderation of cannabinoid pharmacokinetics compared participants aged 16 to 17 with participants aged 26 to 29 and found no strong age effect, which says nothing about adults over 65. The physiologic rationale for expecting differences is reasonable, but the measurement has not been performed. What is 11-hydroxy-THC and why does it matter? It is an active metabolite produced when the liver processes THC. Its concentration relative to THC depends heavily on route. After intravenous dosing the ratio is roughly 1 to 10 or 1 to 20, while after oral dosing it rises to about 0.5 to 1 or 1 to 1, because swallowed cannabis passes through the liver before reaching the circulation. This is the main pharmacologic reason edibles can feel qualitatively different from inhaled cannabis at comparable doses. What blood THC levels did a controlled study find in healthy adults over 65? In a 2014 randomized crossover trial of 12 healthy older adults with a mean age of 72, single oral doses of 3 mg to 6.5 mg of a THC tablet produced peak plasma concentrations of 1.42 to 4.57 ng/mL with time to peak between 67 and 92 minutes, among participants whose peak fell inside the two-hour sampling window. Inter-individual variability was wide, and observed pharmacodynamic effects were smaller than those previously reported in young adults. Does taking CBD alongside THC raise THC blood levels? Controlled studies disagree. A 2026 randomized crossover trial of vaporized cannabis found that adding CBD significantly increased plasma THC and its metabolites compared with THC alone. An earlier randomized study comparing oromucosal THC and CBD spray with matched oral THC found no significant difference in peak concentration, time to peak, or overall exposure. The two used different routes, doses, and populations, and the question remains unresolved. How long does THC stay detectable in blood? Longer than most people expect in frequent users. In 28 chronic frequent cannabis smokers observed under monitored abstinence for up to 33 days, plasma THC remained at or above 2 micrograms per liter in 16 of 28 participants at 48 hours, and THC was still detected in some participants after 30 days. This reflects slow release from lipid-rich tissue rather than ongoing use, and it is why a detectable level is not evidence of recent consumption. Does a blood THC level tell you whether someone is impaired? Poorly. Subjective effect lags behind peak plasma concentration and correlates with it only weakly, a finding that has been replicated since the original controlled comparisons in 1980 and 1981. Chronic users can carry measurable concentrations weeks after last use. For these reasons, a plasma or whole blood threshold is a weak proxy for functional impairment, whatever legal frameworks may assume. Why do two people react so differently to the same dose? Route, product content, tolerance, body composition, and genetics all contribute. Genetics may matter more than commonly assumed: in 43 healthy volunteers given oral THC, people carrying two copies of the CYP2C9*3 variant showed roughly threefold higher THC exposure than people with two copies of the common allele, along with a trend toward greater sedation. That effect size exceeds most of the age differences currently under discussion. How should an older adult approach a first cannabis dose? With a clinician who has the full medication list. The dominant risks in this age group are sedation, unsteadiness, and additive effects with other central nervous system medications, so fall risk rather than blood level should drive the starting dose. Choose one route and hold it constant while titrating, allow a full evening before judging an oral dose, and increase across days rather than within a session. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).